Charles River Laboratories
About: Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Employees: 20,100
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
1% more call options, than puts
Call options by funds: $219M | Put options by funds: $217M
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
0.04% less ownership
Funds ownership: 103.57% [Q1] → 103.53% (-0.04%) [Q2]
3% less capital invested
Capital invested by funds: $7.96B [Q1] → $7.72B (-$242M) [Q2]
8% less funds holding
Funds holding: 554 [Q1] → 511 (-43) [Q2]
15% less repeat investments, than reductions
Existing positions increased: 170 | Existing positions reduced: 200
28% less first-time investments, than exits
New positions opened: 91 | Existing positions closed: 126
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
|
Jefferies
David Windley
|
$195
|
Buy
Upgraded
|
9 Sep 2025 |
|
Evercore ISI Group
Ross Muken
|
$190
|
Outperform
Maintained
|
8 Aug 2025 |
|
JP Morgan
Casey Woodring
|
$160
|
Neutral
Maintained
|
7 Aug 2025 |
|
Barclays
Luke Sergott
|
$165
|
Equal-Weight
Maintained
|
7 Aug 2025 |
|
Citigroup
Patrick Donnelly
|
$200
|
Buy
Upgraded
|
9 Jul 2025 |
Financial journalist opinion
Based on 10 articles about CRL published over the past 30 days
